NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.
NCI Cancer Bulletin publicized board’s resignation over liability concerns.
NCI reassigns project officer John Gohagan.
Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.
Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.
Funding opportunities listed.
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - George Sigounas named the first-ever chief science advisor at NCI
- In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response